Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Effects of Three Years Treatment With Once-Yearly Zoledronic Acid on the Kinetics of Bone Matrix Maturation in Osteoporotic Patients

Gamsjaeger, Sonja and Hofstetter, B and Zwettler, Elisabeth and Recker, Robert and Gasser, Juerg Andreas and Eriksen, Erik Fink and Klaushofer, Klaus and Paschalis, Eleftherios P (2012) Effects of Three Years Treatment With Once-Yearly Zoledronic Acid on the Kinetics of Bone Matrix Maturation in Osteoporotic Patients. Osteoporosis International.


INTRODUCTION: Yearly 5-mg infusions of Zolendronic acid (ZOL) for 3 years have shown pronounced antifracture efficacy. The purpose of the present study was to test whether ZOL affects the kinetics of forming bone material properties maturation.
METHODS: Iliac crest biopsies obtained during the HORIZON-PFT clinical trial were analysed by Raman microspectroscopy in the area of actively bone forming surfaces as a function of tissue age (ZOL = 23, placebo (PLC) = 47)) in trabecular and osteonal bone, to determine ZOL’s effect on bone material quality indices (mineral / matrix, relative proteoglycan content, mineral crystallinity) maturation kinetics.
RESULTS: Mineral / matrix ratio increased in both groups as a function of tissue age, at both osteonal and trabecular bone forming surfaces, ZOL exhibiting the greatest increase in the trabecular surfaces only. The relative proteoglycan content showed a dependency on tissue age in both trabecular and osteonal surfaces, with the ZOL receiving patients exhibiting significantly lower values in the tissue age 8-22 days in the trabecular surfaces. Mineral crystallinity (both crystallite length and thickness) showed a dependence on tissue age, with ZOL-treated patients exhibiting lower crystallite length compared to PLC only in the 8-22 day old tissue at trabecular surfaces, while crystal thickness was lower in the 1-5 day old tissue at both osteonal and trabecular surfaces.
CONCLUSIONS: The results of the present study suggest that once-yearly administration of intravenous ZOL for 3 years in humans does not exert any deleterious effects on the evolution of intrinsic bone material properties at actively forming osteonal and trabecular surfaces, while it may have a beneficial effect on the progression of the mineral to matrix ratio and mineral maturity / crystallinity bone quality indices.

Item Type: Article
Additional Information: The manuscript provides an extension of the data analysis which was published previously: Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP 2010 Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res. (JBMR 2010 Jul 19. [Epub ahead of print])
Keywords: bisphosphonate, bone maturation, osteoporosis, zoledronic acid, Raman spectroscopy
Date Deposited: 02 May 2016 23:45
Last Modified: 02 May 2016 23:45


Email Alerts

Register with OAK to receive email alerts for saved searches.